HRP20100616T1 - Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptorskog kompleksa - Google Patents

Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptorskog kompleksa Download PDF

Info

Publication number
HRP20100616T1
HRP20100616T1 HR20100616T HRP20100616T HRP20100616T1 HR P20100616 T1 HRP20100616 T1 HR P20100616T1 HR 20100616 T HR20100616 T HR 20100616T HR P20100616 T HRP20100616 T HR P20100616T HR P20100616 T1 HRP20100616 T1 HR P20100616T1
Authority
HR
Croatia
Prior art keywords
disorder
compound according
agoraphobia
receptor complex
depression
Prior art date
Application number
HR20100616T
Other languages
English (en)
Croatian (hr)
Inventor
S. Larsen Janus
Teuber Lene
K. Ahring Philip
�stergaard Nielsen Elsebet
Mirza Naheed
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Publication of HRP20100616T1 publication Critical patent/HRP20100616T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20100616T 2006-03-24 2010-11-12 Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptorskog kompleksa HRP20100616T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78527806P 2006-03-24 2006-03-24
DKPA200600426 2006-03-24
DKPA200601327 2006-10-12
US85128406P 2006-10-13 2006-10-13
PCT/EP2007/052766 WO2007110374A1 (en) 2006-03-24 2007-03-22 Benzimidazole derivatives and their use for modulating the gabaa receptor complex

Publications (1)

Publication Number Publication Date
HRP20100616T1 true HRP20100616T1 (hr) 2011-02-28

Family

ID=39456294

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100616T HRP20100616T1 (hr) 2006-03-24 2010-11-12 Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptorskog kompleksa

Country Status (27)

Country Link
US (2) US7902230B2 (pt)
EP (2) EP2001855B1 (pt)
JP (1) JP5260489B2 (pt)
KR (1) KR20080111097A (pt)
CN (1) CN101384559B (pt)
AR (1) AR060084A1 (pt)
AT (1) ATE486856T1 (pt)
AU (1) AU2007229502B2 (pt)
BR (1) BRPI0710203A2 (pt)
CA (1) CA2647252A1 (pt)
CY (1) CY1111603T1 (pt)
DE (1) DE602007010261D1 (pt)
DK (1) DK2001855T3 (pt)
ES (1) ES2355163T3 (pt)
HK (1) HK1132257A1 (pt)
HR (1) HRP20100616T1 (pt)
IL (1) IL192297A (pt)
MX (1) MX2008010885A (pt)
MY (1) MY149855A (pt)
NO (1) NO20084481L (pt)
NZ (1) NZ569438A (pt)
PL (1) PL2001855T3 (pt)
PT (1) PT2001855E (pt)
RU (1) RU2435759C2 (pt)
SI (1) SI2001855T1 (pt)
TW (1) TWI391381B (pt)
WO (1) WO2007110374A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877052B1 (en) 2005-04-13 2009-07-22 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
PL1996556T3 (pl) 2005-12-05 2010-05-31 Neurosearch As Pochodne benzimidazolu i ich zastosowanie do modulowania kompleksu receptorowego GAEAA
TWI391381B (zh) * 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
AU2008345696A1 (en) * 2007-12-21 2009-07-09 Wyeth Llc Benzimidazole compounds
TW201029986A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
WO2010055129A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
WO2010055130A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
TW201029987A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
WO2010055133A1 (en) * 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
TW201029989A (en) * 2008-11-14 2010-08-16 Neurosearch As Novel compounds
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
EP2903980B1 (en) * 2012-10-01 2017-07-19 F. Hoffmann-La Roche AG Benzimidazoles as cns active agents
CN107445845A (zh) * 2017-08-24 2017-12-08 重庆沃肯精细化工有限公司 一种合成氯法齐明关键中间体n‑(4‑氯苯基)‑1，2‑苯二胺的方法
BR112020016269A2 (pt) * 2018-02-11 2020-12-15 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Reguladores derivados de esteroides, método para prepará- los e suas utilizações
HUE060943T2 (hu) * 2018-09-13 2023-04-28 Saniona As A gaba A receptor ligandum
KR102219563B1 (ko) * 2019-02-15 2021-02-24 에스티팜 주식회사 페나진 유도체 제조를 위한 중간체 및 그의 제조방법
CN115003301A (zh) * 2019-10-23 2022-09-02 纽罗塞克医疗公司 用gabaa受体调节剂的癫痫状况的治疗
CN116693555A (zh) * 2022-02-25 2023-09-05 上海赛默罗生物科技有限公司 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
CA2218552C (en) * 1995-04-21 2002-04-16 Neurosearch A/S Benzimidazole compounds and their use as modulators of the gabaa receptor complex
KR100297445B1 (ko) 1995-04-21 2001-10-25 페더 벨링 벤즈이미다졸화합물및감마-아미노부틸산수용체복합체의조절인자로서의그들의용도
EP0934281B1 (en) 1996-10-21 2010-01-06 Neurosearch A/S 1-phenyl-benzimidazole compounds and their use as baga- a? receptor modulators
EP1023286A1 (en) 1997-10-10 2000-08-02 Neurosearch A/S Benzimidazole compounds, pharmaceutical compositions containing the compounds and their use
EP1194410B1 (en) 1999-06-22 2006-01-18 Neurosearch A/S Benzimidazole derivatives and pharmaceutical compositions comprising these compounds
US7335777B2 (en) * 2003-04-03 2008-02-26 Neurosearch A/S Benzimidazole derivatives and their use for modulating the GABAA receptor complex
JP2006522070A (ja) * 2003-04-03 2006-09-28 ニューロサーチ、アクティーゼルスカブ ベンズイミダゾール誘導体及びこれをｇａｂａａ受容体複合体をモジュレートするために使用する方法
JP2008521903A (ja) * 2004-12-01 2008-06-26 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｎ置換されたベンズイミダゾリルＣ−ｋｉｔ阻害剤及びコンビナトリアルベンゾイミダゾールライブラリー
US7809569B2 (en) 2004-12-22 2010-10-05 Enterprise Integration Group, Inc. Turn-taking confidence
EP1877052B1 (en) 2005-04-13 2009-07-22 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
PL1996556T3 (pl) 2005-12-05 2010-05-31 Neurosearch As Pochodne benzimidazolu i ich zastosowanie do modulowania kompleksu receptorowego GAEAA
TWI391381B (zh) * 2006-03-24 2013-04-01 Neurosearch As 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof

Also Published As

Publication number Publication date
KR20080111097A (ko) 2008-12-22
CN101384559A (zh) 2009-03-11
DK2001855T3 (da) 2011-02-07
IL192297A0 (en) 2009-09-22
ATE486856T1 (de) 2010-11-15
AU2007229502B2 (en) 2012-09-20
AU2007229502A1 (en) 2007-10-04
CA2647252A1 (en) 2007-10-04
MY149855A (en) 2013-10-31
CY1111603T1 (el) 2015-10-07
WO2007110374A1 (en) 2007-10-04
HK1132257A1 (en) 2010-02-19
DE602007010261D1 (de) 2010-12-16
RU2008129868A (ru) 2010-04-27
ES2355163T3 (es) 2011-03-23
EP2001855A1 (en) 2008-12-17
AR060084A1 (es) 2008-05-21
US8288418B2 (en) 2012-10-16
JP5260489B2 (ja) 2013-08-14
TWI391381B (zh) 2013-04-01
RU2435759C2 (ru) 2011-12-10
SI2001855T1 (sl) 2011-03-31
US20090036476A1 (en) 2009-02-05
EP2001855B1 (en) 2010-11-03
US20110118259A1 (en) 2011-05-19
EP2319837A1 (en) 2011-05-11
NZ569438A (en) 2011-05-27
US7902230B2 (en) 2011-03-08
BRPI0710203A2 (pt) 2011-05-24
PT2001855E (pt) 2011-01-17
JP2009530353A (ja) 2009-08-27
NO20084481L (no) 2008-12-18
MX2008010885A (es) 2008-09-08
PL2001855T3 (pl) 2011-04-29
IL192297A (en) 2013-11-28
EP2319837B1 (en) 2012-10-31
CN101384559B (zh) 2012-03-14
TW200811113A (en) 2008-03-01

Similar Documents

Publication Publication Date Title
HRP20100616T1 (hr) Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptorskog kompleksa
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
MX2010007936A (es) Anticuerpo anti-nr-10 y su uso.
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2013153479A3 (en) Indole and indazole compounds that activate ampk
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2013000713A1 (es) Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial.
ATE509636T1 (de) Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität
CL2013002504A1 (es) Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion
CL2012002423A1 (es) Método para tratar lupus nefritis activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral; composición farmacéutica que comprende laquinimod y micofenolato mofetil.
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2007003265A1 (es) Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
BRPI0811262A2 (pt) Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
BR112012003464A2 (pt) composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"